Streetbeat News

Stock Prices

PARA

PARAA

Apex Capital Trust has submitted a $43 billion all-cash offer to acquire Paramount Global, proposing to purchase 100% of National Amusements Inc.'s capital stock and assume $15.8 billion in debt. This offer is intended to facilitate a 'go-shop' provision against a deal with Skydance.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:09 pm

BSX

BX

DXCM

EW

JOBY

LOW

MRVL

SLB

Jim Cramer provided stock recommendations on CNBC's 'Mad Money Lightning Round,' highlighting several companies. He recommended buying Lowe’s Companies, Inc. (LOW) ahead of the Federal Reserve's rate cut cycle and expressed positive views on Blackstone Inc. (BX) and Marvell Technology, Inc. (MRVL). He suggested selling Joby Aviation, Inc. (JOBY) and swapping Edwards Lifesciences Corporation (EW) for Boston Scientific (BSX). Cramer also preferred Schlumberger NV (SLB) over Borr Drilling Limited (BORR) and Abbott (ABT) over DexCom, Inc. (DXCM).

Portfolio Pulse from Avi Kapoor

July 31, 2024 | 1:08 pm

FULC

Fulcum Therapeutics shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:07 pm

AMZN

GAME

GameSquare's Q2 2024 report highlights a 10% increase in live-streaming viewership from Q2 2023, reaching 8.5 billion hours watched. Twitch's market share has declined from 70% in Q2 2023 to 60% in Q2 2024, indicating a shift in the live streaming market.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:05 pm

SYTA

Siyata Mobile Inc. (NASDAQ: SYTA) announced a 1-for-18 reverse stock split effective August 2, 2024. The stock will trade on a post-split basis under the same symbol, SYTA, with a new CUSIP number.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:04 pm

MO

Altria Group Inc (NYSE:MO) reported a 3% year-on-year decline in Q2 FY24 revenues to $5.28 billion, missing analyst estimates. The decline was driven by a 5.6% decrease in smokeable products revenue, partially offset by a 4.6% increase in oral tobacco products revenue. Adjusted EPS of $1.31 missed the consensus of $1.34. Despite setbacks, Altria's smoke-free products showed strong performance. The company narrowed its FY24 adjusted EPS guidance to $5.07 – $5.15.

Portfolio Pulse from Shivani Kumaresan

July 31, 2024 | 1:03 pm

GOVX

GeoVax plans a Phase 2 trial for its Gedeptin therapy in first-recurrence head and neck cancer with an immune checkpoint inhibitor. The review of the Phase 1b/2a trial shows acceptable safety and efficacy, with no new safety signals identified. Tumor stabilization and reduction support continued development.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:01 pm

VCNX

Vaccinex announced early-stage SIGNAL-AD trial results for its Pepinemab antibody in Alzheimer's disease, showing a novel mechanism targeting astrocyte activation that delays disease progression. These findings echo results from a Phase 2 Huntington's disease study and were presented at the Alzheimer's Association International Conference by Dr. Eric Siemers.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:01 pm

WBX

Wallbox shares are trading higher after the company announced it received a $45 million investment.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:01 pm

VYGR

Analysts have provided mixed ratings for Voyager Therapeutics (NASDAQ:VYGR) over the past three months, with a range of price targets from $8.00 to $30.00. The average price target has declined by 2.27%. The company has faced a significant revenue decline but maintains strong financial metrics in other areas.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 1:00 pm